一张港股医药板块的行情表,无意间揭示了创新药行业最赤裸的价值分化。截止到2026年2月2日午间市值数据显示:百济神州以约3070亿港元的市值,几乎等同于信达生物、科伦博泰生物与康方生物三者的总和。这一数字关系或许不是简单的数学巧合,亦是资本市场对中国创新药企发展路径与价值评估的集中体现。2025年的全球药企市值TOP50榜单中,11家中国药企集体突围,而百济神州与这三家公司的市值对比,恰好勾勒出从...
Source Link一张港股医药板块的行情表,无意间揭示了创新药行业最赤裸的价值分化。截止到2026年2月2日午间市值数据显示:百济神州以约3070亿港元的市值,几乎等同于信达生物、科伦博泰生物与康方生物三者的总和。这一数字关系或许不是简单的数学巧合,亦是资本市场对中国创新药企发展路径与价值评估的集中体现。2025年的全球药企市值TOP50榜单中,11家中国药企集体突围,而百济神州与这三家公司的市值对比,恰好勾勒出从...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.